We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$911M
AUM Growth
-$47.6M
Cap. Flow
-$18.7M
Cap. Flow %
-2.05%
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$18.3M
2
MCK icon
McKesson
MCK
+$8.31M
3
COO icon
Cooper Companies
COO
+$7.22M
4
ABT icon
Abbott
ABT
+$7.18M
5
CI icon
Cigna
CI
+$6.56M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$32.2M
2
JNJ icon
Johnson & Johnson
JNJ
+$17.7M
3
MDT icon
Medtronic
MDT
+$9.37M
4
PFE icon
Pfizer
PFE
+$6.91M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$6.48M

Sector Composition

Rank Sector Weight
1 Healthcare 95.19%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVS icon
26
CVS Health
CVS
$122B
$12.9M 1.42%
173,000
+2,000
+1% +$168K
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
$12.2M 1.34%
185,000
-15,000
-8% -$866K
NTRA icon
28
Natera
NTRA
$45.9B
$11.8M 1.29%
217,000
+52,000
+32% +$2.5M
BNTX icon
29
BioNTech
BNTX
$23.3B
$11.3M 1.24%
92,000
-17,000
-16% -$2.33M
DHR icon
30
Danaher
DHR
$147B
$11.2M 1.23%
50,760
-5,640
-10% -$1.28M
PRVA icon
31
Privia Health
PRVA
$2.86B
$10.9M 1.19%
395,667
+25,667
+7% +$678K
OM icon
32
Outset Medical
OM
$92.7M
$10.2M 1.12%
37,333
+13,333
+56% +$4.89M
INSP icon
33
Inspire Medical Systems
INSP
$1.73B
$9.14M 1%
38,392
-22,608
-37% -$5.71M
SILK
34
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$8.61M 0.95%
221,255
+25,384
+13% +$1.24M
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
$8.33M 0.91%
41,000
– –
MRTX
36
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.89M 0.87%
215,000
-85,000
-28% -$3.82M
TXG icon
37
10x Genomics
TXG
$7.63B
$7.81M 0.86%
150,000
+75,000
+100% +$3.5M
PFE icon
38
Pfizer
PFE
$154B
$7.67M 0.84%
190,000
-160,000
-46% -$6.91M
PODD icon
39
Insulet
PODD
$9.91B
$7.61M 0.83%
24,000
-5,000
-17% -$1.48M
RVNC
40
DELISTED
Revance Therapeutics, Inc.
RVNC
$7.16M 0.79%
230,000
-208,000
-47% -$6.48M
CYTK icon
41
Cytokinetics
CYTK
$10.8B
$7.01M 0.77%
205,000
-11,322
-5% -$462K
DVAX
42
DELISTED
Dynavax Technologies
DVAX
$7M 0.77%
725,000
-58,519
-7% -$625K
NBIX icon
43
Neurocrine Biosciences
NBIX
$16.8B
$6.94M 0.76%
70,000
-15,000
-18% -$1.56M
XNCR icon
44
Xencor
XNCR
$1.6B
$6.85M 0.75%
250,000
-44,076
-15% -$1.36M
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.67M 0.73%
37,000
+7,000
+23% +$1.34M
ISEE
46
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.66M 0.73%
280,000
-150,000
-35% -$3.28M
VEEV icon
47
Veeva Systems
VEEV
$38.1B
$6.63M 0.73%
37,000
+2,500
+7% +$426K
IMCR icon
48
Immunocore
IMCR
$1.73B
$6.24M 0.68%
131,288
-18,712
-12% -$1.05M
ALHC icon
49
Alignment Healthcare
ALHC
$2.86B
$6.23M 0.68%
1,000,000
+675,000
+208% +$6.44M
RPRX icon
50
Royalty Pharma
RPRX
$25.8B
$5.99M 0.66%
165,000
-50,000
-23% -$1.85M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rhenman & Partners Asset Management held 97 positions worth $911M, down 5% from $958M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2023 filing shows 4 new, 33 increased, 45 reduced and 9 closed positions. Its largest new stake was Viking Therapeutics: 180,000 shares worth $3.12M. The largest sale was Eli Lilly, an estimated $32.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q1 2023 buy was Viking Therapeutics: 180,000 shares worth $3.12M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q1 2023, an estimated $18.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2023 reduction was Medtronic, cutting an estimated $9.37M.
  • Rhenman & Partners Asset Management fully exited Eli Lilly in Q1 2023, selling an estimated $32.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $911M portfolio in Q1 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 9 in Q1 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 5% quarter-over-quarter to $911M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2023, filed 12 May 2023.